Close
Help




JOURNAL

Clinical Medicine Insights: Women's Health

Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection

Submit a Paper


Clinical Medicine Insights: Women's Health 2014:7 1-8

Review

Published on 13 Feb 2014

DOI: 10.4137/CMWH.S10353


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Women's Health

Abstract

Human Immunodeficiency Virus (HIV) is a retrovirus that can result in rare opportunistic infections occurring in humans. The onset of these infections is known as Acquired Immune Deficiency Syndrome (AIDS). Sexual transmission is responsible for the majority of infections 1, resulting in transmission of HIV due to infected semen or vaginal and cervical secretions containing infected lymphocytes. HIV microbicides are formulations of chemical or biological agents that can be applied to the vagina or rectum with the intention of reducing the acquisition of HIV. Tenofovir is an NRTI that is phosphorylated by adenylate kinase to tenofovir diphosphate, which in turn competes with deoxyadeosine 5’-triphosphate for incorporation into newly synthesized HIV DNA. Once incorporated, tenofovir diphosphate results in chain termination, thus inhibiting viral replication. Tenofovir has been formulated into a range of vaginal formulations, such as rings, tablets gels and films. It has been shown to safe and effective in numerous animal models, while demonstrating safety and acceptability in numerous human trials. The most encouraging results came from the CAPRISA 004 clinical trial which demonstrated that a 1% Tenofovir vaginal gel reduced HIV infection by approximately 39%.



Downloads

PDF  (1.89 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Libertas Academica
Having just published in a Libertas Academica journal (Evolutionary Bioinformatics) for the first time, I can attest that I was impressed by the process. Every stage from submission to typesetting and correspondence on matters relating to publishing was simple and efficient. In addition to this, regular updates of the status of the manuscript (with clear explanation of the status) enabled the process to be transparent and informative. I would not hesitate to use Libertas Academica ...
Dr Kevin Arbuckle (University of Liverpool, Merseyside, UK)
More Testimonials

Quick Links


New article and journal news notification services